Bifidobacterium infantis

The infant-gut specialist — now, correctly, Bifidobacterium longum subsp. infantis

All articles checked for accuracy against the GB NHC Register and all sources have citations with verified links to their relevant studies.

A common label name hides a taxonomic update. Bifidobacterium infantis is now classified within Bifidobacterium longum, and that matters for clarity when reading labels and research.

This article explains the correct classification of the organism commonly called “B. infantis,” why it is associated with the breastfed infant gut, what that specialization means, and how strain-specific research should be interpreted. It also covers how live cultures are measured and what WellsparQ declares in its GutBiome 20 product.

Ingredient Snapshot

What it is

A subspecies of Bifidobacterium longum, historically labelled Bifidobacterium infantis.

Where from

Bifidobacterium longum subsp. infantis; isolated from the human infant gut.

Known for

Specialised for consuming human milk oligosaccharides found in breast milk, common in breastfed infant microbiota.

The name on the label is Bifidobacterium infantis, but the taxonomy has moved on, and it is worth getting right from the first line. Since 2008 this organism has been formally classified as a subspecies of Bifidobacterium longum — Bifidobacterium longum subsp. infantis ^¹. The older name B. infantis is still widely used on supplement labels and in the trade, so WellsparQ keeps it on the card for recognition, while this page uses the accurate classification. What is genuinely specific to this organism is its niche: more than any other bifidobacterium, it is the specialist of the breastfed infant gut ^²³.

The taxonomy, told straight

In 2002 three former species — B. longum, B. infantis and B. suis — were merged into a single species, B. longum, on genetic grounds. In 2008 Mattarelli and colleagues resolved the awkwardness by splitting that species into three subspecies: B. longum subsp. longum, B. longum subsp. infantis and B. longum subsp. suis ^¹. So "B. infantis" is not wrong so much as shorthand — it is the infantis subspecies of B. longum.

One practical consequence: standard 16S rRNA gene sequencing — the usual way of profiling gut bacteria — struggles to tell subsp. infantis apart from its close relatives, so accurate identification needs more targeted methods ^³. Anyone relying on the label name should know it points to a subspecies, not a stand-alone species.

Why the infant gut is its home

The distinguishing feature of subsp. infantis is what it eats. Human breast milk is rich in human milk oligosaccharides (HMOs) — complex sugars the infant cannot digest, which appear to be there to feed particular gut microbes rather than the baby directly. Subsp. infantis carries an unusually complete genetic system for importing and breaking down a wide range of these HMOs, which fits it to the milk-fed gut better than most bifidobacteria ^²³. This is why, historically, it was associated with the stools of breastfed infants — the setting in which Tissier first observed bifidobacteria over a century ago ^⁴.

That specialisation is a description of biology, not a benefit claim. It explains where the organism thrives and why it is studied in early life; it does not, on its own, tell you what a supplement will do.

What the named-strain research shows — and its limits

The best-known strain historically labelled "B. infantis" is 35624, studied in adults with irritable bowel syndrome. O'Mahony and colleagues (2005) randomised 77 people with IBS to this strain, to a Lactobacillus strain, or to placebo for eight weeks, and reported symptom and cytokine differences favouring the bifidobacterium ^⁵. It is only fair to add a taxonomic footnote: strain 35624 has itself been re-examined and is now often published as B. longum — a reminder that strain identity and species labels shift, and that trial results belong to the specific strain tested, not to a species name on a jar ^⁵.

Two limits matter. First, findings for 35624 do not transfer to other strains sold as "B. infantis". Second, the NHS notes the overall evidence for live-culture products is limited, and that retail products may differ from the graded material used in research ^⁶. This is context, not a claim about GutBiome 20.

How a live culture is measured

Live cultures are counted, not just weighed. The unit is the colony-forming unit (CFU) — viable cells able to grow into colonies. A milligram figure is the mass of the freeze-dried culture plus carrier; a CFU figure is the verified live count at manufacture. Because viable cells decline over time, the count is a shelf-life matter, and storing the product as directed helps protect it.

In WellsparQ's GutBiome 20, B. infantis is one of three Bifidobacterium species in the blend. The factsheet card notes it is "joined by B. breve to complete the trio". It is declared as a named live culture within the multi-strain formula rather than as a solo headline.

The blend is a bacterial culture preparation; suitability for vegan, kosher or halal diets follows the specific product record.

Suitability and sensible use

Subsp. infantis is a normal early-life gut organism with a long record of use. As with any live-culture product, anyone pregnant, breastfeeding, seriously unwell or immunocompromised should speak to a GP or pharmacist first, and infant use should always be discussed with a health professional ^⁶. Keep to the stated directions and storage.

In short

"B. infantis" is really Bifidobacterium longum subsp. infantis: the milk-adapted specialist of the infant gut, defined by its HMO-eating machinery. The research most often cited — strain 35624 in IBS — belongs to that strain alone, and even its label has shifted with the taxonomy. WellsparQ names it, counts it, and reports the evidence as evidence.